tirzepatide eu approval European Commission grants marketing authorisation for Lilly's Mounjaro® ( tirzepatide), the first GIP and GLP-1 receptor agonist for adults with type 2 diabetes in Europe Lilly releases Zepbound® (tirzepatide) single-dose

Decide if you want daytime protection (morning) or nighttime repair (evening)

P.GeorgeA

A consumer adhesive patch offers neither a standardized dose nor a proven path across the skin, which is the entire problem in a single sentence

Building on the established cardiovascular benefits of GLP-1RAs, engineered nanoplatforms provide an innovative means to further enhance therapeutic efficacy through targeted delivery to cardiac and vascular tissues [321]

Indeed, the Step Up trial showed that some people benefit from a higher weekly dose, resulting in an average weight loss of 20.7% over 72 weeks

Meanwhile, Zepbound patients are suing Eli Lilly after being hospitalized due to severe complications from this GLP-1 drug